Key Insights

Highlights

Success Rate

93% trial completion (above average)

Published Results

21 trials with published results (41%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

5.9%

3 terminated out of 51 trials

Success Rate

92.9%

+6.4% vs benchmark

Late-Stage Pipeline

18%

9 trials in Phase 3/4

Results Transparency

54%

21 of 39 completed with results

Key Signals

21 with results93% success

Data Visualizations

Phase Distribution

46Total
Not Applicable (28)
Early P 1 (1)
P 1 (4)
P 2 (4)
P 3 (7)
P 4 (2)

Trial Status

Completed39
Terminated3
Unknown3
Active Not Recruiting2
Withdrawn2
Not Yet Recruiting1

Trial Success Rate

92.9%

Benchmark: 86.5%

Based on 39 completed trials

Clinical Trials (51)

Showing 20 of 20 trials
NCT02876107Phase 2Active Not Recruiting

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

NCT07474883Early Phase 1Recruiting

Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris

NCT07479004Not ApplicableCompleted

Effect of Cream Paste Containg Pleuran on Selected Skin Dermatoses (Neonatal Pustulosis, Diaper Dermatitis, Perioral Dermatitis).

NCT02411656Phase 2Active Not Recruiting

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

NCT07345195Not ApplicableNot Yet RecruitingPrimary

The Effect of 16-week Dietary Intake of Food Supplements Containing Collagen and MSM on Facial Erythema and Other Skin Parameters

NCT05742347Not ApplicableTerminatedPrimary

Skin Protectant Textile Efficacy Study for Managing Skin Fold Conditions

NCT06369727Phase 1CompletedPrimary

Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design

NCT06369675Phase 1CompletedPrimary

Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design

NCT04290273Not ApplicableWithdrawnPrimary

Characterisation of the Time-course Response of UV-induced Erythema

NCT06016361Not ApplicableUnknownPrimary

Evaluation of a Novel Amino Acid Based Moisturizing Cream as Part of the Daily Standard Skincare Regimen Recommended During Radiation Therapy

NCT04510675Not ApplicableCompletedPrimary

Irritation Potential of Omeza Collagen Matrix Using Modified HRIPT

NCT05300542Not ApplicableCompletedPrimary

Efficacy Study of a Novel Skin Health Product to Reduce an UVB Induced Erythema

NCT05704114Phase 4Completed

Tazarotene 0.045% Lotion for Treating PIE and PIH in Subjects With Acne

NCT04512274Not ApplicableCompleted

Skin Protectant Properties of Omeza Collagen Matrix on Damaged Skin

NCT01659853Phase 3CompletedPrimary

Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea

NCT02490943Not ApplicableCompleted

A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in MS

NCT03352323Phase 3Completed

An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea

NCT03633877Not ApplicableCompletedPrimary

Durapore vs. Hy-Tape to Secure The Endotracheal Tube

NCT01885000Phase 3Completed

Patient-Reported Outcome Of Facial Erythema (PROOF)

NCT03496584Not ApplicableTerminatedPrimary

Effects of Phytonutrients on Vascular Health and Skin in Obese Males

Scroll to load more

Research Network

Activity Timeline